EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Nucleic acid-based therapeutic strategies for modulator-refractory cystic fibrosis-causing variants

Mark D Leahy, Immacolata Zollo, Luka A Clarke, Carlos M Farinha iD

Human Molecular Genetics · 26.06.2026 · 35 (13)

DOI: 10.1093/hmg/ddag058 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Human Molecular Genetics, online erschienen am 26.06.2026. Verfasst von Mark D Leahy und 3 weiteren Autor:innen. Beteiligte Einrichtung: BioISI-Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande, Lisboa 1749-016, Portugal. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 225 Literaturangaben. Gefördert von: ORGESTRA Doctoral Network, Marie Skłodowska-Curie Actions, European Union's Horizon Europe programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystic fibrosis (CF) is a life-limiting autosomal recessive disorder caused by pathogenic variants in the CF transmembrane conductance regulator (CFTR) gene that impair epithelial chloride ion transport, leading to progressive lung dysfunction among other systemic manifestations. Small molecule CFTR modulators have dramatically improved outcomes for people with CF (pwCF) by promoting the trafficking of defective CFTR protein to the cell surface and enhancing its activity. However, a substantial proportion of pwCF harbor genotypes which remain refractory to CFTR modulators and thus lack approved disease-modifying treatments, most commonly nonsense and splicing variants that disrupt CFTR expression at the transcript or translation level. This review delineates the molecular mechanisms underlying modulator-refractory CFTR genotypes, focusing on premature termination codons, nonsense-mediated mRNA decay (NMD), and aberrant pre-mRNA splicing. We examine how these biological phenomena determine and constrain modulator efficacy while simultaneously defining therapeutic entry points. We evaluate emerging DNA-targeted strategies, such as gene replacement and gene editing, alongside RNA-directed approaches, including mRNA replacement, antisense oligonucleotides, CFTR amplifiers, translational readthrough agents and NMD inhibition. Variant-specific sensitivity, reported clinical and preclinical evidence, and practical considerations for implementation are critically assessed. By aligning molecular defect with therapeutic modality, this framework enables rational prioritization of intervention strategies for modulator-refractory CFTR genotypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorHumansNonsense Mediated mRNA DecayOligonucleotides, AntisenseGenetic TherapyAnimalsCodon, NonsenseRNA Splicing

Stichwörter der Autor:innen

RNA therapeuticsantisense oligonucleotidescystic fibrosisgene therapymRNA splicingpremature termination codon

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorOligonucleotides, AntisenseCFTR protein, humanCodon, Nonsense

Autor:innen und Institutionen

  • BioISI-Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande, Lisboa 1749-016, Portugal.
  • Advanced Disease Modelling, Targeted Drug Discovery and Gene Therapy (ADVANTAGE), Department of Pharmacological and Pharmaceutical Sciences, Faculty of Medicine, KU Leuven, 3001 Leuven, Belgium.

ORCID-Profile: Carlos M Farinha

Förderung

  • ORGESTRA Doctoral Network
  • Marie Skłodowska-Curie Actions
  • European Union's Horizon Europe programme
  • Fondazione Fibrosi Cistica Ricerca
  • Cystic Fibrosis Foundation
  • Cystic Fibrosis Trust
  • Fundação para a Ciência e a Tecnologia
  • European Union’s Horizon Europe programme

Zitieren

APA

Leahy, M. D., Zollo, I., Clarke, L. A., & Farinha, C. M. (2026). Nucleic acid-based therapeutic strategies for modulator-refractory cystic fibrosis-causing variants. Human Molecular Genetics, 35(13). https://doi.org/10.1093/hmg/ddag058

Vancouver

Leahy MD, Zollo I, Clarke LA, Farinha CM. Nucleic acid-based therapeutic strategies for modulator-refractory cystic fibrosis-causing variants. Human Molecular Genetics. 2026;35(13). doi:10.1093/hmg/ddag058

BibTeX
@article{Leahy2026,
  author = {Leahy, Mark D and Zollo, Immacolata and Clarke, Luka A and Farinha, Carlos M},
  title = {Nucleic acid-based therapeutic strategies for modulator-refractory cystic fibrosis-causing variants},
  journal = {Human Molecular Genetics},
  year = {2026},
  volume = {35},
  number = {13},
  doi = {10.1093/hmg/ddag058}
}
Kostenlos starten →